AQR Capital Management’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$193M Sell
888,913
-261,833
-23% -$58.1M 0.09% 311
2025
Q4
$263M Buy
1,150,746
+223,904
+24% +$51M 0.14% 188
2025
Q3
$210M Buy
926,842
+328,850
+55% +$67M 0.13% 201
2025
Q2
$110M Sell
597,992
-176,114
-23% -$32.7M 0.09% 318
2025
Q1
$159M Sell
774,106
-674,261
-47% -$131M 0.16% 155
2024
Q4
$256M Sell
1,448,367
-263,367
-15% -$48.4M 0.33% 49
2024
Q3
$333M Buy
1,711,734
+307,306
+22% +$57.4M 0.46% 28
2024
Q2
$238M Sell
1,404,428
-134,055
-9% -$22.2M 0.36% 46
2024
Q1
$278M Sell
1,538,483
-306,614
-17% -$52.8M 0.47% 30
2023
Q4
$286M Buy
1,845,097
+348,011
+23% +$50.7M 0.54% 24
2023
Q3
$223M Buy
1,497,086
+331,662
+28% +$48.7M 0.46% 36
2023
Q2
$155M Sell
1,165,424
-28,800
-2% -$4.22M 0.33% 65
2023
Q1
$189M Sell
1,194,224
-227,583
-16% -$34.8M 0.41% 44
2022
Q4
$229M Sell
1,421,807
-36,141
-2% -$5.54M 0.52% 29
2022
Q3
$196M Sell
1,457,948
-208,400
-13% -$29.9M 0.48% 27
2022
Q2
$253M Sell
1,666,348
-131,592
-7% -$20.1M 0.57% 22
2022
Q1
$291M Sell
1,797,940
-232,348
-11% -$33.8M 0.55% 24
2021
Q4
$275M Buy
2,030,288
+57,832
+3% +$6.83M 0.5% 33
2021
Q3
$213M Buy
1,972,456
+103,628
+6% +$11.8M 0.39% 45
2021
Q2
$209M Sell
1,868,828
-387,539
-17% -$43.6M 0.36% 54
2021
Q1
$243M Sell
2,256,367
-205,311
-8% -$22M 0.4% 52
2020
Q4
$260M Sell
2,461,678
-1,210,419
-33% -$116M 0.46% 39
2020
Q3
$319M Sell
3,672,097
-1,653,574
-31% -$156M 0.54% 29
2020
Q2
$512M Buy
5,325,671
+2,296,582
+76% +$202M 0.83% 16
2020
Q1
$231M Buy
3,029,089
+1,257,587
+71% +$107M 0.39% 53
2019
Q4
$157M Buy
1,771,502
+623,364
+54% +$51.8M 0.18% 148
2019
Q3
$86.5M Sell
1,148,138
-1,789,134
-61% -$123M 0.1% 240
2019
Q2
$212M Sell
2,937,272
-2,039,418
-41% -$160M 0.24% 120
2019
Q1
$400M Buy
4,976,690
+950,737
+24% +$77.8M 0.42% 48
2018
Q4
$371M Sell
4,025,953
-967,494
-19% -$85.1M 0.43% 57
2018
Q3
$472M Buy
4,993,447
+931,390
+23% +$88.3M 0.45% 54
2018
Q2
$380M Sell
4,062,057
-938,798
-19% -$91.7M 0.38% 60
2018
Q1
$473M Buy
5,000,855
+507,695
+11% +$55.8M 0.51% 40
2017
Q4
$435M Buy
4,493,160
+752,859
+20% +$71M 0.46% 46
2017
Q3
$332M Buy
3,740,301
+2,845,510
+318% +$217M 0.4% 57
2017
Q2
$64.9M Sell
894,791
-46,033
-5% -$3.09M 0.09% 303
2017
Q1
$61.3M Buy
940,824
+347,710
+59% +$21.9M 0.08% 333
2016
Q4
$37.1M Sell
593,114
-63,576
-10% -$3.88M 0.05% 456
2016
Q3
$41.4M Buy
656,690
+132,726
+25% +$8.59M 0.06% 411
2016
Q2
$32.4M Sell
523,964
-544,432
-51% -$33.2M 0.06% 441
2016
Q1
$61M Sell
1,068,396
-283,076
-21% -$15.8M 0.11% 255
2015
Q4
$80.1M Buy
1,351,472
+125,319
+10% +$7.22M 0.14% 200
2015
Q3
$66.7M Sell
1,226,153
-2,241,420
-65% -$146M 0.13% 212
2015
Q2
$233M Sell
3,467,573
-3,259,104
-48% -$213M 0.46% 40
2015
Q1
$394M Buy
6,726,677
+2,718,701
+68% +$164M 0.9% 8
2014
Q4
$262M Buy
4,007,976
+1,501,101
+60% +$94.6M 0.55% 20
2014
Q3
$145M Sell
2,506,875
-773,075
-24% -$42.9M 0.4% 47
2014
Q2
$185M Buy
3,279,950
+314,100
+11% +$16.5M 0.5% 30
2014
Q1
$152M Buy
2,965,850
+1,953,268
+193% +$98.7M 0.46% 38
2013
Q4
$53.5M Buy
1,012,582
+703,435
+228% +$34.6M 0.16% 165
2013
Q3
$13.8M Buy
+309,147
New +$13.7M 0.05% 455

Other funds holding ABBV

AQR Capital Management's ABBV Position: Q1 2026 in Review

AQR Capital Management reduced its AbbVie (ABBV) stake by 23% in Q1 2026, selling an estimated $58.1M and leaving 888,913 shares worth $193M. The position accounts for 0.09% of the portfolio, ranked #311.

AQR Capital Management first reported a position in ABBV in Q3 2013 and has held it in 51 quarters since. The position peaked at $512M in Q2 2020. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • AQR Capital Management held 888,913 shares of AbbVie worth $193M as of Q1 2026.
  • AQR Capital Management sold 261,833 AbbVie shares in Q1 2026, an estimated $58.1M.
  • AbbVie made up 0.09% of AQR Capital Management's portfolio in Q1 2026, its #311 holding.
  • AQR Capital Management first reported a position in AbbVie in Q3 2013 and has held it in 51 quarters since.
  • AQR Capital Management's AbbVie position peaked at $512M in Q2 2020.
  • 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.